MedDataX Logo

Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease

NCT ID: NCT01904240

Last Updated: 2014-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The cause of Parkinson's disease (PD) is currently unknown. Both environmental and genetic factors have been found to contribute to PD pathogenesis. The pathology of PD is distributed throughout the entire nervous system including the central, peripheral, and enteric nervous system. There is evidence that inflammation plays a major role in neurodegeneration in PD. In both the striatum and substantia nigra of PD patients activated microglia were found and proinflammatory cytokines (TNF, IL-1B, IL-6, iNOS) are increased in the CSF. An inflammation-driven animal model has emerged and has been widely accepted as a model of the disease based on lipopolysaccharide (LPS) induced neurotoxicity. LPS is an endotoxin found on the outer membrane of gram negative bacteria and humans are exposed to LPS through the intestinal tract. The intestinal tract and thus the enteric nervous system serve as a conduit to the central nervous system. It has been posited that the inflammatory process could gain access to the lower brainstem via the vagal nerve and then ascend through the basal mid- and forebrain until it reaches the cerebral cortex, producing various pre-motor and motor symptoms of PD along the way. LPS may be one of the inflammatory triggers involved in this process. Systemic exposure to bacterial endotoxin can be determined by measuring plasma LPS binding protein (LBP). A study of 9 patients with early PD (median Hoehn and Yahr stage 2) and age matched controls found that the PD subjects had a significantly lower mean level of plasma LBP compared to control subjects. The aim of the research plan is to establish LBP as a potential biomarker for PD across a spectrum of disease severity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's disease patients

Patients with Parkinson's disease

No interventions assigned to this group

Subjects without Parkinson's disease

Control subjects without Parkinson's disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a clinical diagnosis of Parkinson's disease by United Kingdom Parkinson Disease Society Brain Bank criteria will be recruited.
* Hoehn and Yahr stage 1-5
* Parkinson's disease symptomatic treatment will be allowed.


* No evidence of GI symptoms other than minor hematochezia attributable to hemorrhoids.
* No evidence of symptoms of Parkinson's disease.
* Matching in age and gender to the Parkinson's disease patients.

Exclusion Criteria

* Treatment with medications that may induce parkinsonism (metoclopramide, typical, or atypical antipsychotic agents)
* Known diagnosis of inflammatory bowel disease.
* Symptomatic functional GI disease that significantly impairs intestinal mobility such as scleroderma or use of GI motility drugs.
* Acute illness requiring immediate hospitalization.
* Presence of short bowel syndrome or severe malnutrition with ideal body weight \< or = 90%


* Presence of Parkinson's disease or its symptoms.
* Treatment with medications that may induce parkinsonism (metoclopramide, typical, or atypical antipsychotic agents)
* Known diagnosis of inflammatory bowel disease.
* Symptomatic functional GI disease that significantly impairs intestinal mobility such as scleroderma or use of GI motility drugs.
* Acute illness requiring immediate hospitalization.
* Presence of short bowel syndrome or severe malnutrition with ideal body weight \< or = 90%
Minimum Eligible Age

30 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rush University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gian D Pal, MD

Role: PRINCIPAL_INVESTIGATOR

Rush University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12102401-IRB01

Identifier Type: -

Identifier Source: org_study_id